Dose escalation trials typically follow a structured approach. Patients are divided into small groups or cohorts. The first cohort receives a low dose of the drug, and if no severe side effects are observed, the next cohort receives a higher dose. This process continues until the MTD is identified. Various models, such as the 3+3 design and the Bayesian model, are employed to guide dose escalation decisions.